BETA: Please send your feedback!
Flexion Therapeutics
NAS:FLXN
Biotechnology
$551.95mm
SMALL cap
$14.58
(2.60%)
17.0144%
since start of 2019
—
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- 3
-
CF
-
PP
-
WC
-
DP
-
CH
-
ES
-
WS
-
CG
-
EP
-
CM
-
FL
-
GD
- —
- 1
- 2
- 3
- 4
- 5
About
Biotechnology
Founded 2007
Flexion Therapeutics, Inc. is a pharmaceutical company, which focuses on the development and commercialization of novel, local therapies. The firm specializes in treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.
website
Headquarters
Executives
Name | Title | Gender |
Kerry A. Wentworth | Vice President-Regulatory Affairs & Quality | Female |
Scott D. Kelley, MD | Vice President-Medical Affairs | Male |
Patrick J. Mahaffy | Chairman | Male |
Michael D. Clayman, MD | President, Chief Executive Officer, CFO & Director | Male |
Neil Bodick, MD, PhD | Chief Scientific Officer | Male |
Yamo Deniz, MD | Chief Medical Officer | Male |
Rose Villandry | Vice President-Human Resources | Female |
Dan Leblanc | Senior Vice President-CMC Operations | Male |
Scott Young | Senior Director-Corporate Communications & IR | Male |
Mindful Investing Summary
- —
- 1
- 2
- 3
- 4
- 5
-
Carbon Footprint — N/A
-
Pollution Prevention — N/A
-
Water Conservation — N/A
-
Data & Privacy Protection — N/A
-
Consumer Health, Wellness & Safety — N/A
-
Employee Ownership, Satisfaction, Benefits & Pay — N/A
-
Workplace Health and Safety — N/A
-
Integrity of Corporate Governance — N/A
-
Ethical Practices — N/A
-
Usage of Conflict Materials — N/A
-
Forced Labor — N/A
-
Diversity of Corporate Leadership 3
Flexion Therapeutics - Competitors and Related Companies
How Flexion Therapeutics stacks up to its peers in the Biotechnology industry or with competing business segments.
Flexion Therapeutics
NAS:FLXN
Biotechnology
$551.95mm
SMALL cap
$14.58
(2.60%)
17.0144%
since start of 2019
—
Loading…